ACTION ALERT: Urge the FDA to Say YES to Accelerated Approval for Duchenne Therapies for Children
March 12, 2014
We urge the Food and Drug Administration (FDA) to use the Accelerated Approval pathway for approval and access to safe, effective therapies for Duchenne Muscular Dystrophy – the leading genetic killer of children that impacts 1 out of every 3,500 boys born in the United States. It’s time for the FDA to Say Yes and make this the first generation of Duchenne survivors.
Sign up for updates straight to your inbox.